Arnav Agarwal Profile picture
Mar 3, 2022 13 tweets 15 min read Read on X
🔥 Our latest @WHO living guidance on drugs for #COVID19:

Severe/critical:
✅steroids, IL-6RB, baricitinib
🔷REGN-COV
🔶other JAK2i, plasma

Non-severe:
🔷molnupiravir, REGN-COV, sotrovimab
🔶steroids
🚫plasma

All:
🔶remdesivir, ivermectin
🚫HCQ, LPV/r

bit.ly/3pAK6Oe
Important considerations/caveats:
✨Choice between baricitinib & IL-6RB for severe/critical COVID-19 depends on availability & clinical/contextual factors.
✨In non-severe illness, molnupiravir, sotrivimab & casirivimab-imdevimab are weakly recommended for those at highest risk.
Some other considerations/caveats:
✨Other JAK2i should be considered for severe/critical illness only if baricitinib is not available.
✨Ivermectin (across severities) & plasma (for severe/critical) should be considered only in the context of a clinical trial.
🌟 This iteration: a new weak/conditional recommendation for molnupiravir in patients with non-severe illness at highest risk of hospitalization, with mitigation strategies.

Treatment reduces hospitalization risk & time to symptom resolution; may have small survival benefit.
🔷 Among patients with non-severe illness, the recommendation is limited to those at highest risk of hospitalization who are likely to derive greatest benefit.

This is considering potential long-term harms (e.g. risk of malignancy) & uncertainty re: identifying highest risk pts.
🌟 This iteration also incorporates two updates to prior recommendations:

1. Conditional recommendations for casirivimab-imdevimab in non-severe & severe/critical COVID-19 now restricted to cases where rapid genotyping is available & confirms susceptible SARS-CoV-2 variant.
🌟 The other change:

2. New trial data has resulted in ongoing evidence review by the guideline panel to update the previous conditional recommendation against remdesivir across severities; update anticipated in next iteration.
A living systematic review & network meta-analysis, led by @RSiemieniuk & @rominabrigpet with contributions from @jessbartoszko, @DenaZera, @AnilaQasim, @Elena_Kum et al, informed recommendations.

Check out the 🔥 website with evidence readily accessible: covid19lnma.com
This work contributes to collaborative living guidance produced by @WHO and the #MAGIC Evidence Ecosystem on drugs to prevent #COVID19, also published via @bmj_latest.

This is an incredible cross-collaborative effort - honoured and lucky to be part of it.
Associated guideline in the @WHO portal: bit.ly/3tlXdqi

Associated guideline in @theMAGICapp: bit.ly/3Gk5ldZ

Associated LNMA: bit.ly/3lIKNnP
What is in the pipeline? The @WHO portal summarizes therapeutics to come (dot = week of time).

In deciding which therapeutics to cover, WHO considers factors including extent of available evidence, and makes a judgment on whether & when additional evidence may be anticipated.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Arnav Agarwal

Arnav Agarwal Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ArnavAgarwalMD

Dec 7, 2021
🔊Our latest @WHO living guidance on treatments for #COVID19, out today:

For severe/critical:
✅steroids
✅IL-6 RB
🟨mAb
🟧convalescent plasma🔥

For non-severe:
🟨mAb
🟧steroids
🚫convalescent plasma🔥

For both:
🟧remdesivir
🟧ivermectin
🚫HCQ
🚫LPV/r

bit.ly/3pAK6Oe ImageImage
Two recommendations:
🌟against administering convalescent plasma for non-severe covid-19.
🌟against administering convalescent plasma for severe or critical covid-19, except in the context of a clinical trial. Image
A living systematic review & network meta-analysis, led by @RSiemieniuk & @rominabrigpet with contributions from @jessbartoszko, @DenaZera, @AnilaQasim, @Elena_Kum et al, informed recommendations.

Now with a 🔥🔥 website with evidence readily accessible: covid19lnma.com. Image
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(